GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » Cash Flow from Investing

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Cash Flow from Investing : HK$-33.1 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Sichuan Kelun-Biotech Biopharmaceutical Co spent HK$0.0 Mil on purchasing property, plant, equipment. It gained HK$0.0 Mil from selling property, plant, and equipment. It spent HK$0.0 Mil on purchasing business. It gained HK$0.0 Mil from selling business. It spent HK$0.0 Mil on purchasing investments. It gained HK$0.0 Mil from selling investments. It paid HK$0.0Mil for net Intangibles purchase and sale. And it paid HK$0.0 Mil for other investing activities. In all, Sichuan Kelun-Biotech Biopharmaceutical Co gained HK$0.0 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Investing Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Investing Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Investing
-115.57 -35.90 -1,121.58

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
Sep21 Dec21 Jun22 Sep22 Dec22 Jun23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial - -189.93 156.80 - -

Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-33.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sichuan Kelun-Biotech Biopharmaceutical Co  (HKSE:06990) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Sichuan Kelun-Biotech Biopharmaceutical Co's purchase of property, plant, equipment for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co spent HK$0.0 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Sichuan Kelun-Biotech Biopharmaceutical Co's sale of property, plant, equipment for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co gained HK$0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Sichuan Kelun-Biotech Biopharmaceutical Co's purchase of business for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co spent HK$0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Sichuan Kelun-Biotech Biopharmaceutical Co's sale of business for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co gained HK$0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Sichuan Kelun-Biotech Biopharmaceutical Co's purchase of investment for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Sichuan Kelun-Biotech Biopharmaceutical Co's sale of investment for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co gained HK$0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Sichuan Kelun-Biotech Biopharmaceutical Co's net Intangibles purchase and sale for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co paid HK$0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Sichuan Kelun-Biotech Biopharmaceutical Co's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co paid HK$0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Sichuan Kelun-Biotech Biopharmaceutical Co's cash from other investing activities for the three months ended in Dec. 2023 was HK$0.0 Mil. It means Sichuan Kelun-Biotech Biopharmaceutical Co paid HK$0.0 Mil for other investing activities.


Sichuan Kelun-Biotech Biopharmaceutical Co Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.
Executives
Liu Gexin 2201 Interest of corporation controlled by you
Si Chuan Ke Lun Yao Ye Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Cheng Du Ke Lun Jing Chuan Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Wellington Management Group Llp 2102 Investment manager
Merck & Co., Inc. 2201 Interest of corporation controlled by you
Merck Sharp & Dohme Llc 2101 Beneficial owner
Ke Lun Guo Ji Fa Zhan You Xian Gong Si 2101 Beneficial owner
Li Jun 2201 Interest of corporation controlled by you
Zhou Quan 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates L.p. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund Gp Associates Ltd. 2201 Interest of corporation controlled by you
Idg Breyer Capital Fund L.p. 2201 Interest of corporation controlled by you
Victory Rhythm Limited 2201 Interest of corporation controlled by you
Wealthy Linkage Limited 2101 Beneficial owner
Ho Chi Sing 2201 Interest of corporation controlled by you

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines